Axsome Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AXSM Nasdaq 2834 www.axsome.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Axsome Therapeutics, Inc.

Axsome Therapeutics Upside Tied to Auvelity FDA Decision, $2 Billion Sales Opportunity Seen, UBS Says - Apr 10th, 2026 9:26 am
Is This Healthcare Stock a Millionaire Maker? - Apr 8th, 2026 4:08 pm
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 - Apr 8th, 2026 5:00 am
Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions - Apr 1st, 2026 5:00 am
Axsome Therapeutics (AXSM) Valuation Check After Recent Share Price Cooling - Mar 30th, 2026 3:06 pm
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report? - Mar 27th, 2026 9:30 am
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - Mar 25th, 2026 3:44 pm
Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report? - Mar 25th, 2026 9:30 am
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - Mar 13th, 2026 9:36 am
Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference - Mar 12th, 2026 4:46 pm
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth - Mar 10th, 2026 12:10 pm
2 Under-the-Radar Stocks to Buy and Hold - Mar 10th, 2026 11:33 am
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates - Mar 10th, 2026 4:31 am
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision - Mar 9th, 2026 2:03 pm
Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision - Mar 5th, 2026 9:06 pm
Axsome Therapeutics, Inc. (AXSM): A Bull Case Theory - Feb 28th, 2026 11:02 am
Axsome Opens CLARITY Trial As Solriamfetol Targets Underserved MDD Patients - Feb 27th, 2026 12:13 pm
Axsome Therapeutics Highlights Auvelity Momentum, 600-Rep Sales Push, and April 30 ADA PDUFA at Oppenheimer Conf. - Feb 25th, 2026 7:10 pm
Axsome Therapeutics to Participate in Upcoming Investor Conferences - Feb 25th, 2026 5:00 am
AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - Feb 24th, 2026 10:08 am